Department of Pediatrics, Division of Hematology/Oncology, Baylor College of Medicine, Houston, Texas, USA.
Texas Children's Cancer and Hematology Centers, Texas Children's Hospital, Houston, Texas, USA.
Pediatr Blood Cancer. 2022 Aug;69(8):e29696. doi: 10.1002/pbc.29696. Epub 2022 Apr 22.
Pyruvate kinase (PK) deficiency is a rare, congenital red blood cell disorder caused by a single gene defect. The spectrum of genotypes, variants, and phenotypes are broad, commonly requiring a multimodal approach including enzyme and genetic testing for accurate and reliable diagnosis. Similarly, management of primary and secondary sequelae of PK deficiency varies, mainly including supportive care with transfusions and surgical interventions to improve symptoms and quality of life. Given the risk of acute and long-term complications of PK deficiency and its treatment, regular monitoring and management of iron burden and organ dysfunction is critical. Therefore, all children and adolescents with PK deficiency should receive regular hematology care with visits at least every 6 months regardless of transfusion status. We continue to learn more about the spectrum of symptoms and complications of PK deficiency and best practice for monitoring and management through registry efforts (NCT03481738). The treatment of PK deficiency has made strides over the last few years with newer disease-modifying therapies being developed and studied, with the potential to change the course of disease in childhood and beyond.
丙酮酸激酶(PK)缺乏症是一种罕见的先天性红细胞疾病,由单个基因缺陷引起。基因型、变异体和表型的范围很广,通常需要采用包括酶和基因检测在内的多模态方法进行准确可靠的诊断。同样,PK 缺乏症的原发性和继发性后遗症的管理也各不相同,主要包括输血和手术干预的支持性护理,以改善症状和生活质量。鉴于 PK 缺乏症及其治疗的急性和长期并发症的风险,铁负荷和器官功能障碍的定期监测和管理至关重要。因此,所有 PK 缺乏症的儿童和青少年都应定期接受血液学护理,无论输血情况如何,至少每 6 个月就诊一次。通过注册研究(NCT03481738),我们不断了解 PK 缺乏症的症状和并发症的范围以及监测和管理的最佳实践。过去几年,PK 缺乏症的治疗取得了进展,新的疾病修饰疗法正在开发和研究中,有可能改变儿童期及以后的疾病进程。